Roche的授精性药物在早期乳腺癌存活率方面有显著改善,标志着口服SERD治疗的突破。 Roche's giredestrant drug showed significant improvement in early-stage breast cancer survival, marking a breakthrough for oral SERD treatment.

Roche于2025年11月18日宣布,其实验性药物(口服SERD)在早期、荷尔蒙受体阳性、HER2-阴性乳腺癌患者中显著改善了无侵入性疾病存活率,标志着SERD首次在辅助环境中表现出这种好处。 Roche announced on November 18, 2025, that its experimental drug giredestrant, an oral SERD, significantly improved invasive disease-free survival in patients with early-stage, hormone receptor-positive, HER2-negative breast cancer, marking the first time a SERD has shown such benefits in the adjuvant setting. 涉及4 100多名病人的第三阶段LidERA试验显示,在统计学上取得了重要成果,具有有利的安全特征。 The Phase III lidERA trial, involving over 4,100 patients, showed statistically significant results with a favorable safety profile. 这些结果基于预先计划的临时分析, 支持Geredestrant有可能成为早期乳腺癌护理的新标准, 影响约70%的病例。 The findings, based on a pre-planned interim analysis, support giredestrant’s potential to become a new standard of care for early-stage breast cancer, which affects about 70% of cases. 成果将与监管机构分享,并在一次医疗会议上介绍。 Results will be shared with regulators and presented at a medical meeting.